An ALS mouse model with a permeable blood-brain barrier benefits from systemic cyclosporine A treatment

Journal of Neurochemistry

Volumn 88, Issue 4, 2004, Pages 821-826

  Kirkinezos, Ilias G ^a   Hernandez, Dayami ^a   Bradley, Walter G ^a   Moraes, Carlos T ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Amyotrophic lateral sclerosis; Blood brain barrier; Cyclosporine A; Mitochondria

Indexed keywords

ALANINE; COPPER ZINC SUPEROXIDE DISMUTASE; CYCLOSPORIN; CYCLOSPORIN A; GENE PRODUCT; GLYCINE; GLYCOPROTEIN P; IMMUNOSUPPRESSIVE AGENT; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 1A; MULTIDRUG RESISTANCE PROTEIN 1B; SUPEROXIDE DISMUTASE; TRITIUM; UNCLASSIFIED DRUG;

AGE; AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; CENTRAL NERVOUS SYSTEM; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE MODEL; DRUG BRAIN LEVEL; DRUG EFFECT; FEMALE; GENETICS; HUMAN; LIVER; MALE; METABOLISM; MITOCHONDRION; MOUSE; MOUSE MUTANT; MULTIDRUG RESISTANCE; MUSCLE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROBABILITY; SEX DIFFERENCE; SPINAL CORD; SURVIVAL RATE; TISSUE DISTRIBUTION; TRANSGENIC MOUSE; TREATMENT OUTCOME; VALIDATION PROCESS; WILD TYPE;

ANIMALIA; MUS MUSCULUS;

EID: 1042289650     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2003.02181.x     Document Type: Article

References (44)

1. Appel S. H., Stewart S. S., Appel V., Harati Y., Mietlowski W., Weiss W. and Belendiuk G. W. (1988) A double-blind study of the effectiveness of cyclosporine in amyotrophic lateral sclerosis. Arch. Neurol. 45, 381-386.
2. Begley D. J., Squires L. K., Zlokovic B. V., Mitrovic D. M., Hughes C. C., Revest P. A. and Greenwood J. (1990) Permeability of the blood-brain barrier to the immunosuppressive cyclic peptide cyclosporin A. J. Neurochem. 55, 1222-1230.
3. Bernardi P., Broekemeier K. M. and Pfeiffer D. R. (1994) Recent progress on regulation of the mitochondrial permeability transition pore; a cyclosporin-sensitive pore in the inner mitochondrial membrane. J. Bioenerg. Biomembr. 26, 509-517.
4. Brooks B. P., Merry D. E., Paulson H. L., Lieberman A. P., Kolson D. L. and Fischbeck K. H. (1998) A cell culture model for androgen effects in motor neurons. J. Neurochem. 70, 1054-1060.
5. Buki A., Okonkwo D. O. and Povlishock J. T. (1999) Postinjury cyclosporin A administration limits axonal damage and disconnection in traumatic brain injury. J. Neurotrauma 16, 511-521.
6. Clipstone N. A. and Crabtree G. R. (1992) Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 357, 695-697.
7. Crompton M., Virji S. and Ward J. M. (1998) Cyclophilin-D binds strongly to complexes of the voltage-dependent anion channel and the adenine nucleotide translocase to form the permeability transition pore. Eur. J. Biochem. 258, 729-735.
8. Cudkowicz M. E., McKenna-Yasek D., Sapp P. E., Chin W., Geller B., Hayden D. L., Schoenfeld D. A., Hosler B. A., Horvitz H. R. and Brown R. H. (1997) Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis. Ann. Neurol. 41, 210-221.
9. Dubinsky J. M., Brustovetsky N., Pinelis V., Kristal B. S., Herman C. and Li X. (1999) The mitochondrial permeability transition: the brain's point of view. Biochem. Soc. Symp. 66, 75-84.
10. Ferrante R. J., Klein A. M., Dedeoglu A. and Beal M. F. (2001) Therapeutic efficacy of EGb761 (Gingko biloba extract) in a transgenic mouse model of amyotrophic lateral sclerosis. J. Mol. Neurosci. 17, 89-96.
11. Fridovich I. (1995) Superoxide radical and superoxide dismutases. Annu. Rev. Biochem. 64, 97-112.
12. Galat A. and Metcalfe S. M. (1995) Peptidylproline cis/trans isomerases. Prog. Biophys. Mol. Biol. 63, 67-118.
13. Gaudette M., Hirano M. and Siddique T. (2000) Current status of SOD1 mutations in familial amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 1, 83-89.
14. Guegan C., Vila M., Rosoklija G., Hays A. P. and Przedborski S. (2001) Recruitment of the mitochondrial-dependent apoptotic pathway in amyotrophic lateral sclerosis. J. Neurosci. 21, 6569-6576.
15. Gurney M. E., Pu H., Chiu A. Y., Dal Canto M. C., Polchow C. Y., Alexander D. D., Caliendo J., Hentati A., Kwon Y. W., Deng H. X. et al. (1994) Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264, 1772-1775.
16. Hammond J., Le Q., Goodyer C., Gelfand M., Trifiro M. and LeBlanc A. (2001) Testosterone-mediated neuroprotection through the androgen receptor in human primary neurons. J. Neurochem. 77, 1319-1326.
17. Harrison P. C. and Madwed J. B. (1999) Anti-LFA-1α reduces the dose of cyclosporin A needed to produce immunosuppression in heterotopic cardiac transplanted rats. J. Heart Lung Transplant 18, 279-284.
18. Keep M., Elmer E., Fong K. S. and Csiszar K. (2001) Intrathecal cyclosporin prolongs survival of late-stage ALS mice. Brain Res. 894, 327-331.
19. Kirkinezos I., Hernandez D., Bradley W. G. and Moraes C. T. (2003) Regular exercise is beneficial to a mouse model of amyotrophic lateral sclerosis. Ann. Neurol. 53, 804-807.
20. Kowaltowski A. J., Castilho R. F. and Vercesi A. E. (1996a) Opening of the mitochondrial permeability transition pore by uncoupling or inorganic phosphate in the presence of Ca2+ is dependent on mitochondrial-generated reactive oxygen species. FEBS Lett. 378, 150-152.
21. Kowaltowski A. J., Castilho R. F., Grijalba M. T., Bechara E. J. and Vercesi A. E. (1996b) Effect of inorganic phosphate concentration on the nature of inner mitochondrial membrane alterations mediated by Ca2+ ions. A proposed model for phosphate-stimulated lipid peroxidation. J. Biol. Chem. 271, 2929-2934.
22. Liu J., Farmer J. D. Jr, Lane W. S., Friedman J., Weissman I. and Schreiber S. L. (1991) Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 66, 807-815.
23. Martin L. J. (1999) Neuronal death in amyotrophic lateral sclerosis is apoptosis: possible contribution of a programmed cell death mechanism. J. Neuropathol. Exp. Neurol. 58, 459-471.
24. Matsumoto S., Friberg H., Ferrand-Drake M. and Wieloch T. (1999) Blockade of the mitochondrial permeability transition pore diminishes infarct size in the rat after transient middle cerebral artery occlusion. J. Cereb. Blood Flow Metab. 19, 736-741.
25. Militello A., Vitello G., Lunetta C., Toscano A., Maiorana G., Piccoli T. and La Bella V. (2002) The serum level of free testosterone is reduced in amyotrophic lateral sclerosis. J. Neurol. Sci. 195, 67-70.
26. Mulder D. W. (1982) Clinical limits of amyotrophic lateral sclerosis. Adv. Neurol. 36, 15-22.
27. Nelson L. M. (1995) Epidemiology of ALS. Clin. Neurosci. 3, 327-331.
28. O'Keefe S. J., Tamura J., Kincaid R. L., Tocci M. J. and O'Neill E. A. (1992) FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin. Nature 357, 692-694.
29. Pardo C. A., Xu Z., Borchelt D. R., Price D. L., Sisodia S. S. and Cleveland D. W. (1995) Superoxide dismutase is an abundant component in cell bodies, dendrites, and axons of motor neurons and in a subset of other neurons. Proc. Natl Acad. Sci. USA 92, 954-958.
30. Raoul C., Estevez A. G., Nishimune H., Cleveland D. W., deLapeyriere O., Henderson C. E., Haase G. and Pettmann B. (2002) Motoneuron death triggered by a specific pathway downstream of Fas. potentiation by ALS-linked SOD1 mutations. Neuron 35, 1067-1083.
31. Ripps M. E., Huntley G. W., Hof P. R., Morrison J. H. and Gordon J. W. (1995) Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. Proc. Natl Acad. Sci. USA 92, 689-693.
32. Rosen D. R., Siddique T., Patterson D., Figlewicz D. A., Sapp P., Hentati A., Donaldson D., Goto J., O'Regan J. P., Deng H. X. et al. (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362, 59-62.
33. Schinkel A. H., Wagenaar E., van Deemter L., Mol C. A. and Borst P. (1995) Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Invest 96, 1698-1705.
34. Schinkel A. H., Wagenaar E., Mol C. A. and van Deemter L. (1996) P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 97, 2517-2524.
35. Schinkel C., Zimmer S., Durda P. J., Hocherl E., Herndon D. N. and Faist E. (1997) Kinetics of soluble interleukin-2 receptor after mechanical and burn trauma. J. Burn Care Rehabil. 18, 210-213.
36. Szabo I. and Zoratti M. (1991) The giant channel of the inner mitochondrial membrane is inhibited by cyclosporin A. J. Biol. Chem. 266, 3376-3379.
37. Takeuchi H., Kobayashi Y., Ishigaki S., Doyu M. and Sobue G. (2002) Mitochondrial localization of mutant superoxide dismutase 1 triggers caspase-dependent cell death in a cellular model of familial amyotrophic lateral sclerosis. J. Biol. Chem. 277, 50966-50972.
38. Tindall R. S. (1992) Immunointervention with cyclosporin A in autoimmune neurological disorders. J. Autoimmun. 5, 301-313.
39. Tsuji A. (1998) P-glycoprotein-mediated efflux transport of anticancer drugs at the blood-brain barrier. Ther. Drug Monit. 20, 588-590.
40. Uchino H., Elmer E, Uchino K., Li P. A., He Q. P., Smith M. L. and Siesjo B. K. (1998) Amelioration by cyclosporin A of brain damage in transient forebrain ischemia in the rat. Brain Res. 812, 216-226.
41. Wallace D. C. and Melov S. (1998) Radicals r'aging. Nat. Genet. 19, 105-106.
42. Weiner L. P. (1980) Possible role of androgen receptors in amyotrophic lateral sclerosis. A hypothesis. Arch. Neurol. 37, 129-131.
43. Zamzami N., Susin S. A., Marchetti P., Hirsch T., Gomez-Monterrey I., Castedo M. and Kroemer G. (1996) Mitochondrial control of nuclear apoptosis. J. Exp. Med. 183, 1533-1544.
44. Zoratti M. and Szabo I. (1995) The mitochondrial permeability transition. Biochim. Biophys. Acta 1241, 139-176.